The tender offer is for €51.29 per share, representing a 13% premium on Recordati’s share price before the takeover was first disclosed.
The FDA granted priority review for Datroway based on results from the TROPION-Breast02 Phase III trial.
The CHMP opinion is based on results from the Phase III BREAKWATER trial.
In the MATCH clinical trial, 26 patients received macrophage therapy while 24 had standard care.
Cases of syphilis and gonorrhoea have tripled and quadrupled, respectively, since 2015 – highlighting the need for sound treatment and prevention methods.
Gilead will donate vials of its antifungal medication AmBisome to help global efforts in eliminating visceral leishmaniasis.
